Praxis Precision Medicines Inc (PRAX) Reports Q3 2023 Financial Results
Company's Cash Position Supports Runway into Q1 2025, R&D Expenses Decrease by 43.5% Year-Over-Year
Praxis Precision Medicines Inc License Agreement Precision Medicines Inc Praxis June Praxis Cerebrum Praxis Solidus
Source: yahoo.com